Home
>
Dana Farber Research
>
Clinical Trials:
Participating Institutions
Current Trials
Pending Trials
Corollary Studies
Recently Completed Trials
Read The Latest WMP
Program News >>
Email this page to a friend >
The trials below have been completed and are closed to enrollment.
An Open Label, Multicenter Phase-2 Study of Single-Agent Enzastaurin HCl in Previously Treaed Waldenstrom's Macroglobulinemia or Multiple Myeloma
Campath-1H for patients with relapsed and refractory WM
Extended Rituximab for patients with WM
Phase II Clinical Trial of combination therapy with bortezomib, dexamethasone, and rituximab in patients with WM
Phase II Clinical Trial of RAD001 in relapsed/refractory lymphoma
Phase II Clinical Trial of Sildenafil Citrate in WM
Phase II Study of CC-5013 (Lenalidomide , Revlimid(tm)) and rituximab in Waldenstrom's macroglobulinemia
Phase II Study of Combination Therapy with bortezomib and rituximab in patients with relapsed/refractory Waldenstrom’s macroglobulinemia.
Phase II Study of Imatinib Mesylate (Gleevec) in Relapsed or Refractory WM
Phase II Study of Perifosine in Patients with Relapsed/Refractory WM
Phase II Study of Simvastatin in WM
Phase II Study of Thalidomide and Rituximab for patients with WM
Phase II Study of VELCADE (PS-341) in WM
Rituximab plus Fludarabine for patients with WM
Legal Statements
|
Privacy Policy
